Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynavax Technologies initiates a proof-of-mechanism clinical trial of the TLR7 and TLR9 inhibitor, DV1179, in systemic lupus erythematosus (SLE) patients.
Subscribe to our email newsletter
Initiation of the trial entitles Dynavax to receive a $6m milestone payment from GlaxoSmithKline (GSK) under their worldwide strategic alliance.
GSK has an exclusive option to obtain a license to the program following completion of this trial.
The first of two stages of the trial will evaluate ascending doses of DV1179 for safety and tolerability in SLE patients, each of whom will receive eight weekly injections of DV1179.
The second stage of the trial will evaluate DV1179’s mechanism of action via inhibition of type 1 interferon by enrolling additional SLE patients in selected dose groups.
Dynavax president and chief medical officer Tyler Martin said at the completion of this trial, they will be able to determine if DV1179 can reduce interferon levels in lupus patients.
"Excessive production of type 1 interferons is thought to be a critical factor in the pathogenesis of lupus," Martin added.